Vascular endothelial growth factor tyrosine kinase inhibitors (VEGF-TKIs) have been the
mainstay of treatment for patients with advanced renal cell carcinoma (RCC). Despite its …

Enhancer of zeste homolog 2 (EZH2), a histone methyltransferase and a catalytic
component of PRC2, catalyzes tri-methylation of histone H3 at Lys 27 (H3K27me3) to …

The development and immune evasion of cancer stem cells (CSCs) limit the efficacy of
currently available anticancer therapies. Recent studies have shown that epigenetic …

The treatment landscape of metastatic renal cell carcinoma (RCC) has been revolutionized
over the past two decades, bringing forth an era in which more than a dozen therapeutic …

Platinum drugs are used in first-line to treat ovarian cancer, but most of the patients
eventually generate resistance after treatment with these drugs. Although both c-Myc and …

Receptor tyrosine kinases (RTKs), a category of transmembrane receptors, have gained
significant clinical attention in oncology due to their central role in cancer pathogenesis …

Circular RNAs (circRNAs) play critical roles in clear cell renal cell carcinoma (ccRCC).
However, their involvement in sunitinib resistance remains largely unknown. Herein, we …

The poor prognosis of pancreatic cancer is primarily due to the development of resistance to
therapies, including gemcitabine. The long noncoding RNA PVT1 (lncRNA PVT1) has been …

Simple Summary Renal cell carcinoma is particularly characterized by its high
vascularization and dense immune cells infiltration. The angiogenesis blockade in …

Angiogenesis, the formation of new blood vessels from preexisting one, represents a critical
process for oxygen and nutrient supply to proliferating cells, therefore promoting tumor …